文献速递免疫规划

产肠毒素大肠杆菌dmLT舌下或口服免疫的1期剂量递增研究

A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
PubMed 文献 · Vaccine · 2018-12-15

该1期剂量递增研究在80名健康成人中评估舌下或口服dmLT(1-50μg)的安全性与免疫原性。疫苗安全耐受,但免疫原性中等,舌下给药后血清抗体应答有限,口服给药抗体滴度一般显著更高。

要点

  • dmLT经舌下或口服给药在1-50μg剂量下安全耐受,呕吐或腹泻罕见。
  • 舌下免疫后血清抗dmLT IgA和IgG及中和抗体应答中等,25或50μg时4倍增长比例最高38%。
  • 口服给药后抗体滴度一般显著高于舌下给药。

核心结论

  • dmLT疫苗配方经舌下或口服给药至50μg剂量安全,但免疫原性仅中等。

研究设计与样本

  • 1期剂量递增研究,80名健康成人志愿者接受3剂dmLT(第1、15、29天),剂量1-50μg。

主要发现

  • 疫苗安全耐受,仅罕见呕吐或腹泻。
  • 舌下免疫后血清抗dmLT IgA和IgG及中和抗体应答中等。
  • 25或50μg剂量时血清IgA和IgG滴度升高,但4倍增长比例最高38%。
  • 完成全部3剂者中IgA和IgG的4倍增长比例均为43%。
  • 口服给药后抗体滴度一般显著高于舌下给药。

局限性

  • 舌下或口服给药至50μg剂量免疫原性仅中等,需更高剂量和更好配方研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The public health burden of Enterotoxigenic Escherichia coli (ETEC) is high but no vaccine is specifically approved to prevent ETEC infections. METHODS: We performed a Phase 1, dose escalation study (1-50 µg) evaluating the sublingual (SL) delivery of the double mutant heat-labile toxin LTR192G/L211A (dmLT) in 80 healthy adult volunteers. The primary objective was safety and the secondary was the immunogenicity of the dmLT. Subjects received 3 doses of dmLT at days 1, 15, and 29. Subjects receiving the first dose at each dosage level were observed overnight in a research facility. The second and third doses were administered on an outpatient basis. Data from cohorts 1-4 were used to select the cohort 5 dose (25 µg), comparing SL and oral routes. RESULTS: The vaccine appeared safe and well tolerated with only rare development of vomiting or diarrhea. The serum anti-dmLT IgA and IgG and neutralizing antibody responses were modest after any of the SL immunizations. Serum IgA and IgG titers were increased at the higher antigen doses (25 or 50 µg) but the percent with 4-fold increases was at best 38% for both IgA and IgG. The 4-fold increase among subjects receiving all 3 doses was 43% for both IgA and IgG. Antibody titers following oral administration were, in general, significantly higher than after SL. The frequency of IgA- or IgG-ASCs in circulation were somewhat vaccine dose dependent and were detected at a moderate level. However, antibodies in saliva or stool were rarely detected. Post-vaccination increases in T cells or cytokine production were also infrequent. CONCLUSION: The dmLT vaccine formulation evaluated here was safe but only moderately immunogenic at doses up to 50 µg when administered by the SL or oral route. Studies at higher doses with better formulations appear warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bernstein DI, Pasetti MF, Brady R, et al. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization. Vaccine. 2018. PMID: 30563789. doi:10.1016/j.vaccine.2018.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。